Ribosomal protein L21 pseudogene 134 (RPL21P134)

Ribosomal protein L21 pseudogene 134 (RPL21P134) is classified as a processed pseudogene derived from the parent ribosomal protein L21 gene (RPL21)[5][2][3]. Like other ribosomal protein pseudogenes, RPL21P134 has high sequence similarity to the functional RPL21 gene but has accumulated disabling mutations and is not known to be transcribed or translated into a functional protein[7]. Pseudogenes in this family are generally considered "genomic fossils" and do not fulfill the protein-coding or structural roles of their parent gene, nor are they known to have direct regulatory, disease, or pharmacological roles[7][5]. There is no direct evidence that RPL21P134 is involved in disease or targeted by any drugs, making it irrelevant for therapeutic targeting or biomarker development[5][7]. Its primary relevance is in genome annotation and evolutionary studies of the ribosomal protein gene family. Notes: - RPL21P134 is distinct from the functional gene RPL21, which encodes a component of the 60S ribosomal subunit[9][8]. - Some pseudogenes may have regulatory non-coding RNA functions, but there is no evidence that RPL21P134 possesses this activity[7]. - The existence of many ribosomal protein pseudogenes is typical for this gene family due to high expression and retrotransposition events[7]. If further functional or mechanistic evidence for RPL21P134 becomes available (such as regulatory or disease-relevant non-coding RNA roles), this classification could change. For now, it should not be considered a drug target, biomarker, or functional disease gene[5][7][2][3].

Other names

RPL21_61_1788RPL21P134